Format

Send to

Choose Destination
Future Oncol. 2019 Jun;15(18):2175-2190. doi: 10.2217/fon-2018-0858. Epub 2019 Apr 23.

Safety and effectiveness of classical and alternative sunitinib dosing schedules for metastatic renal cell carcinoma: a meta-analysis.

Author information

1
Meta Research, Evidera, London, W6 8BJ, UK.
2
Formerly Meta Research, Evidera, Waltham, MA 02451, USA.
3
Pfizer Inc, Groton, CT 06340, USA.
4
Pfizer, Inc., New York, NY 10017, USA.
5
Meta Research, Evidera, Waltham, MA 02451, USA.
6
Pfizer Oncology, 75668 Paris, France.
7
Stanford University Medical Center, Stanford, CA 94304, USA.
8
Pfizer, 15451 Athens, Greece.

Abstract

The optimal dosing schedule to maintain the effectiveness of sunitinib for metastatic renal cell carcinoma - while reducing toxicity - remains an important clinical question. A meta-analysis of randomized trials and observational studies assessed the relative treatment effects of 4/2, 2/1 and transitional-2/1 schedules on outcomes and adverse events using Bayesian network meta-analysis methods. Treatment with 2/1 reduced the risk of disease progression or death by 25% and had lower odds of hand-and-foot syndrome compared with the 4/2. A numerical but not 'statistical' benefit in progression-free survival was observed with the transitional-2/1 compared with 4/2. Alternative schedules with the 2/1 and transitional-2/1 may be more clinically beneficial in metastatic renal cell carcinoma than the 4/2 schedule.

KEYWORDS:

alternative dosing schedule; metastatic renal cell carcinoma; sunitinib; transitional dosing schedule

PMID:
31010323
DOI:
10.2217/fon-2018-0858
Free full text

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center